Xbrane Biopharma AB (publ) (XBRANE.ST)
Makes cheaper versions of expensive cancer and eye disease drugs.
10.00-0.02%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-70.3%
The outlook
Xbrane Biopharma is trading near the lower end of its 52-week range, with analyst estimates averaging around 50% above the current price of 10. The stock shows mixed momentum against its moving averages, while the neutral overall score reflects balanced sentiment among followers.
What’s behind the score
Price trendMixed vs its moving averages
52-week range14% of the way from its 52-week low to high
Price targetAvg target +50% vs current price
Market cap
$206.1M
52-wk high
38.10
52-wk low
5.42
50-day avg
10.60
200-day avg
9.76
Trailing P/E
—